Cell-free biologics delivering the full bioactive payload of cord PRP — without the complexity of live cell therapies.
Highly purified and concentrated EV solution
Cross-tissue mobility including dermal, mucosal & blood-brain barrier penetration
ISO 9001 certified manufacturing
FDA & AATB donor screening protocols
Regenerative medicine is evolving toward acellular, scalable biologics that retain therapeutic potency while reducing regulatory and operational complexity. Extracellular vesicles (EVs) derived from umbilical cord PRP represent one of the most biologically active and efficient platforms available today.
🧬 Angiogenesis Support
Promotes vascular regeneration and tissue oxygenation.
🔥 Anti-Inflammatory Signaling
Modulates immune responses through paracrine mechanisms.
🧱 Tissue Remodeling
Supports wound healing and structural repair pathways.
🔄 Scalable Manufacturing
Expanded from a single PRP harvest for research and commercial applications.
Unlike cord blood cells, EVs:
Penetrate dermal and mucosal layers
Cross the blood-brain barrier
Protect bioactive cargo via lipid bilayer membrane
Allow surface modification for targeted receptor delivery
EVs contain:
Proteins
Lipids
RNA
Growth factors
Immune mediators
All delivered in a stable, transportable nanostructure.
Orthopedics
Neurology
Dermatology
Immunology
Drug Delivery Research
Translational Medicine
EV-based therapies are now viewed as a powerful complement to existing regenerative solutions.
Developed by Leo Corps, Inc. and its subsidiary Novoxa, ExCyte™ is a highly purified and concentrated extracellular vesicle solution engineered for regenerative medicine and biomedical research. Produced under strict quality oversight, ExCyte™ is ISO 9001 certified to ensure consistent quality, purity, and traceability.
| Feature | ExCyte™ | Standard Biologic |
|---|---|---|
| Purification Level | Highly Concentrated | Variable |
| Donor Screening | FDA & AATB | Varies |
| Manufacturing Oversight | ISO 9001 | Not Always |
| Scalability | High | Limited |
Donor screening per FDA & AATB guidelines
ISO accredited biobanking laboratory
CLIA certified processing labs
Cord blood otherwise discarded after therapeutic use
Full traceability and quality control
Speak directly with our biologics team to explore how Cord PRP-Derived EVs can strengthen your research or product line.
Call 833-LEO-7183
Email: info@leocorps.org
Leo Corps, Inc. is a California-based biotechnology and bioservices company focused on accelerating biomedical research and regenerative medicine through the manufacturing, processing, and global distribution of high-quality human cell and acellular products. The company operates ISO-accredited biobanking laboratories and CLIA-certified processing facilities to ensure biospecimens are consistently dependable and ethically sourced.
All donor materials are screened in accordance with FDA and American Association of Tissue Banks (AATB) guidelines for human tissue. Manufacturing and processing occur within ISO 9001 certified environments with full documentation, traceability, and quality control oversight.
Extracellular vesicles are provided for research and investigational applications in accordance with applicable regulatory frameworks. Organizations should consult their regulatory teams regarding specific clinical use cases.
Umbilical cord blood is ethically obtained from consenting donors following full-term births. Each donor is screened according to FDA and AATB standards. Cord blood that would otherwise be discarded is processed under controlled laboratory conditions to ensure purity and consistency.
Extracellular vesicle preparations should be stored frozen at recommended temperatures (typically -80°C for long-term storage unless otherwise specified). Avoid repeated freeze-thaw cycles to preserve structural integrity and bioactivity.
Short-term storage conditions and transport guidelines are provided with each batch.
Thaw gently on ice or at 4°C
Avoid vigorous vortexing
Use sterile technique during transfer
Minimize freeze-thaw cycles
Follow recommended dilution protocols
Detailed handling SOPs are available upon request.
When stored under proper frozen conditions, EVs maintain structural integrity and biological activity for extended periods. Stability testing includes particle concentration, purity verification, and bioactivity validation.
Lot-specific stability and quality documentation are available for qualified organizations.
Yes. Because EVs are derived from PRP, expansion from a single cord blood donation can support scalable production volumes. This makes EVs well-suited for research programs, clinical development pathways, and commercial manufacturing needs.
The lipid bilayer structure of EVs allows for potential surface modification or payload customization in research settings. Custom solutions may be available depending on application requirements.